Welcome to our dedicated page for ProKidney news (Ticker: PROK), a resource for investors and traders seeking the latest updates and insights on ProKidney stock.
ProKidney Corp. (Nasdaq: PROK) generates frequent news flow as a late clinical-stage biotechnology company focused on chronic kidney disease (CKD) and autologous cellular therapy. News coverage for ProKidney often centers on clinical trial milestones for its lead product candidate, rilparencel (also known as REACT®), regulatory interactions with the U.S. Food and Drug Administration (FDA), and financial and corporate updates relevant to investors following PROK stock.
Readers can expect updates on Phase 2 and Phase 3 studies, including the REGEN-007 and REGEN-006 (PROACT 1) trials in patients with advanced CKD and diabetes. Press releases have highlighted statistically significant and clinically meaningful changes in estimated glomerular filtration rate (eGFR) slope, safety findings such as the absence of rilparencel-related serious adverse events in reported analyses, and FDA confirmation that eGFR slope can serve as a surrogate endpoint for an accelerated approval pathway. These items help investors and observers track the progress of rilparencel through late-stage development.
ProKidney news also includes quarterly financial results, cash runway commentary, and disclosures about research and development and general and administrative expenses. SEC-related announcements, such as at-the-market equity offering arrangements and changes in jurisdiction of incorporation, are commonly reported through press releases and associated Form 8-K filings. In addition, the company regularly announces participation in scientific and investor conferences, including American Society of Nephrology Kidney Week presentations and healthcare investment conferences where senior management discusses clinical data and corporate strategy.
For anyone monitoring PROK news, this stream of clinical, regulatory, financial, and conference-related updates provides insight into ProKidney’s efforts to advance rilparencel as a potential new treatment option for patients with advanced CKD and diabetes and to manage the company’s capital and public market presence.
ProKidney Corp. (Nasdaq: PROK) announced the approval of its Phase 3 proact 1 study protocol for the REACT® candidate by the UK’s MHRA, following FDA approval in the US. The UK sites will start patient recruitment, expanding the clinical trial beyond North America. ProKidney also received positive feedback from the EMA for its Phase 3 development program, critical for a future MAA. The proact program aims to enroll 600 patients and proactively prevent chronic kidney disease progression. Interim results are expected in late 2024 for proact 1.
ProKidney Corp. (Nasdaq: PROK) announced it will present five posters on chronic kidney disease (CKD) during the ASN Annual Meeting in Orlando, FL, from November 3-6, 2022. Topics include CKD prevalence, gender differences in progression, and the effects of SGLT2 inhibitors. The company will hold an investor briefing on November 3. The lead product candidate, REACT™, aims to slow CKD progression and has received RMAT designation. CKD affects approximately 75 million people in the U.S. and Europe, with significant healthcare costs associated.
ProKidney Corp. (Nasdaq: PROK) announced that CEO Dr. Tim Bertram will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 1:30 p.m. ET in New York, NY. Investors can access the live webcast via ProKidney's investor relations website. The company focuses on cellular therapeutics for chronic kidney disease (CKD), particularly their lead product REACT™, which has received RMAT designation and supports ongoing Phase 3 clinical trials. CKD affects approximately 75 million people in the U.S. and Europe, posing significant health risks.
ProKidney Corp. (Nasdaq: PROK) announced that CEO Dr. Tim Bertram will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, in New York, NY. The discussion will cover commercialization strategies, cost reduction, and manufacturing scalability for their lead product REACT™, a novel therapy for chronic kidney disease (CKD). A live webcast will be available on their investor relations site. ProKidney aims to slow CKD progression and improve kidney function through innovative cellular therapies.
ProKidney Corp. (Nasdaq: PROK) has appointed Glenn Schulman as Senior Vice President of Investor Relations, effective immediately. With nearly 20 years of experience in investor relations and corporate communications, Schulman aims to enhance ProKidney's visibility and shareholder value as it advances its lead product, REACT™, through clinical development. REACT™ is a patented cellular therapy for chronic kidney disease, currently in Phase 3 trials. CFO James Coulston expressed confidence in Schulman's expertise to foster long-term success for the company.
ProKidney Corp. (Nasdaq: PROK) reported financial results for Q2 2022 following its business combination with Social Capital Suvretta Holdings. The company secured $596.5 million in gross proceeds to support its Phase 3 program for REACT™, aimed at treating chronic kidney disease (CKD). As of June 30, 2022, ProKidney's cash and equivalents were $21.9 million, up from $20.6 million at the end of 2021. R&D expenses rose to $11.6 million, while G&A expenses surged to $9.2 million. The diluted net loss per share stood at $(0.12), compared to $(0.09) in Q2 2021.
ProKidney Corp. (Nasdaq: PROK) announces the addition of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors, enhancing its leadership team. Maraganore, with over 35 years of experience, previously founded Alnylam Pharmaceuticals and is an advisor at several investment funds. Fox brings over 25 years of healthcare investment banking experience, previously associated with Nuvation Bio and CitiGroup. Both appointees will support ProKidney’s mission to advance its REACT™ therapy for chronic kidney disease during a critical development phase.
ProKidney Corp. (Nasdaq: PROK) has appointed Dr. Kerry Cooper as Senior Vice President of Medical Affairs, enhancing its leadership in treating Chronic Kidney Disease (CKD). Dr. Cooper, previously with AstraZeneca, brings nearly 40 years of clinical and industry experience, having led nephrology programs and established strong ties within the kidney advocacy community. His expertise will be crucial as ProKidney advances its candidate REACT™, a novel therapy aimed at reversing CKD's progression. This appointment comes as ProKidney prepares for further clinical studies.
ProKidney Corp., focused on chronic kidney disease (CKD), commenced trading on Nasdaq as "PROK" on July 12, 2022, following a merger with Social Capital Suvretta Holdings Corp. III. The company raised approximately $597 million in gross proceeds, primarily to fund ongoing Phase 2 and 3 clinical trials for its lead therapy, REACT™. This innovative cell therapy aims to improve kidney function in late-stage CKD patients. The firm is guided by an experienced management team and has filed over 200 patents, underscoring its commitment to advancing CKD treatments.